You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF), the most common of the interstitial lung diseases, occurs in about 128,000 people, with 48,000 new cases diagnosed annually in the US. The typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandapos; of the lungs causing an irreversible loss of the tissueandapos;s ability to transport oxygen. Co-morbid pulmonary ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Wireless sensor and telemedicine to screen for sleep apnea in elderly adults

    SBC: ZANSORS LLC            Topic: NIMHD

    ABSTRACT Obstructive sleep apnea OSA is the most common type of sleep apnea OSA affects an estimated million adults and of all children in the US OSA results in tiredness depression and fatigue and has several associated common comorbidities It is believed that over of OSA remains undiagnosed The prevalence of OSA increases with age and if untreated increases the risk of ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: 102

    The overall objective of the proposed research is to develop and conduct clinical translation of a novel visualization technology that provides minimally invasive surgeons the ability to visualize normally invisible internal anatomy together with organ surfacesThe technology addresses a long standing need in minimally invasive laparoscopic surgery to see inside and around a structure before dissec ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery

    SBC: Nido Surgical, Inc            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    SBC: THERATARGET, INC.            Topic: 102

    SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of symptomshepatocellular carcinomaHCCis detected at advanced stages inof casesfor which theyear survival rate isand atyears it isThe only curative option for advanced HCC is surgical liver resection an ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Exhaled breath drug detection using differential mobility spectrometry

    SBC: VOX BIOMEDICAL LLC            Topic: NIDA

    Project Summary We have conducted a pilot study using some of the elements in the present proposal that provide support for the notion that a well selected set of psychomotor/performance tasks can be used to predict driving impairment via a simulated program. Adding these two approaches to the existing STTR project will add significantly to the value of the data focused on developing a breath test ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of PAR Pepducins for the Treatment of Atopic Dermatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government